Overhauling Teva: Conversations With Jeremy Levin And Michael Hayden
Teva CEO Jeremy Levin and the CSO he hired, Michael Hayden, want to re-focus the company on innovative R&D and selective generics opportunities, and that means an overhaul of the R&D organization and new priorities for business development. Levin and Hayden spoke to IN VIVO about their goals and shaping these activities following a widely anticipated investor briefing on December 11 in New York City.
You may also be interested in...
Chairman Philip Frost cited “slight differences” with Teva’s board as the reason that Jeremy Levin resigned. Analysts on a same day call grilled the chairman on Teva’s practice to deny corporate executives a seat on its board, and on the resulting misalignment of board and management objectives.
A year after leaving Teva as a full-time employee, Bill Marth will succeed Albany Molecular Research’s founding CEO at the beginning of 2014. The company believes an increase in capital availability and a return to R&D spending will fuel a trend toward outsourced pharma services.
An appeals court ruling on July 26 favoring a faster route to a generic Copaxone brings to the fore longstanding issues of what its regulatory path might look like and how Teva will cope with the erosion of its top product’s sales.